Skip to main content
Cachet Pharmaceutical Co., Ltd. logo

Cachet Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002462 ISIN · CNE100000SN0 LEI · 300300CBONJS7HUOCX64 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,441 across all filing types
Latest filing 2022-03-29 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002462

About Cachet Pharmaceutical Co., Ltd.

https://www.cachet.com.cn

Cachet Pharmaceutical Co., Ltd. specializes in the distribution and retail of pharmaceutical products and medical devices. The company operates an extensive wholesale network and a chain of retail pharmacies, providing comprehensive supply chain solutions to healthcare institutions and end-consumers. Its core operations include the procurement, storage, and logistics of western medicines, traditional Chinese medicines, and high-value medical consumables. Cachet Pharmaceutical emphasizes modern logistics management and professional pharmaceutical services, leveraging a robust distribution infrastructure to ensure the efficient delivery of healthcare products. The company also focuses on hospital supply chain integration and community-based retail services to enhance healthcare accessibility.

Recent filings

Filing Released Lang Actions
独立董事2021年度述职报告(薛健)
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2021 Annual Report" and details the independent director's activities, attendance at meetings, opinions on company matters, investigations, committee roles, and efforts to protect investor rights during the year 2021. It is a detailed report on the independent director's duties and oversight for the year, not a general annual report or financial statement. It does not contain financial data or audit results but focuses on governance and supervisory activities by the independent director. This fits best under the category of Board/Management Information (MANG), which includes announcements or reports related to board members' activities and governance roles. The document length is 2853 characters, which is consistent with a detailed director report rather than a full annual report or audit report. Therefore, the classification is MANG with high confidence.
2022-03-29 Chinese
独立董事2021年度述职报告(熊焰)
Board/Management Information Classification · 95% confidence The document is titled 'Independent Director 2021 Annual Work Report' and contains detailed descriptions of the independent director's activities, attendance at meetings, opinions on company matters, and oversight responsibilities during the year 2021. It is a formal report by an independent director summarizing their duties and observations for the year. This type of document is a management or supervisory report related to governance and oversight rather than a full annual report, audit report, or other financial filings. It does not contain financial statements or earnings data but focuses on governance and director duties. Therefore, it fits best under the category of Board/Management Information (MANG), which includes announcements or reports related to board members and their roles.
2022-03-29 Chinese
年度股东大会通知
AGM Information Classification · 95% confidence The document is a detailed notice about the convening of the 2021 Annual General Meeting (AGM) of 嘉事堂药业股份有限公司. It includes information about the meeting date, location, agenda items such as the 2021 annual work reports, financial statements, profit distribution plan, and other shareholder meeting procedures. It also contains instructions for voting, proxy forms, and legal compliance statements. The document does not contain the actual annual report or financial statements but rather the announcement and details for the upcoming AGM. The length is about 4761 characters, which is consistent with a detailed meeting notice rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2022-03-29 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 16th meeting of the 6th Supervisory Board of 嘉事堂药业股份有限公司. It includes approvals of various reports such as the 2021 Supervisory Board Work Report, 2021 Business Summary, 2021 Internal Control Self-Evaluation Report, 2021 Financial Statements, 2021 Profit Distribution Plan, 2021 Annual Report and its summary, 2021 Social Responsibility Report, and other related proposals. The document repeatedly states that these reports are available elsewhere (e.g., on 巨潮资讯网) and that these reports require approval at the shareholders' meeting. The document itself does not contain the full annual report or financial statements but is a formal announcement of the Supervisory Board's meeting resolutions and approvals. The length is about 2638 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is an official announcement of meeting resolutions and approvals, not the full Annual Report (10-K) or other detailed reports themselves.
2022-03-29 Chinese
2022年度日常关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from 嘉事堂药业股份有限公司 regarding the expected related party transactions for the year 2022. It includes details about the nature of transactions, related parties, pricing policies, and independent directors' opinions. The document is relatively short (2131 characters) and serves as a disclosure or announcement rather than a full financial report. It does not contain comprehensive financial statements or detailed financial analysis. The content aligns with regulatory disclosure requirements about related party transactions rather than an annual report, interim report, or audit report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-03-29 Chinese
2021年社会责任报告
Environmental & Social Information Classification · 95% confidence The document is titled "2021 年企业社会责任报告" (2021 Corporate Social Responsibility Report) and contains detailed sections on the company's social responsibility activities, governance, internal control, and business performance for the year 2021. It references compliance with Shenzhen Stock Exchange guidelines on social responsibility and covers environmental, social, and governance (ESG) factors extensively. The content focuses on the company's social responsibility initiatives, governance practices, and sustainability efforts rather than purely financial results or audit opinions. Therefore, this document fits the category of Environmental & Social Information (SR). The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement or summary.
2022-03-29 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.